Introduction: Calcium phosphate cements (CPCs) have been widely used as an alternative to biological grafts as they present excellent biocompatibility and osteoconductive properties. An additional advantage is their self-setting nature, which makes them injectable and allows the use of a minimally invasive surgical procedure during clinical use. However, CPCs do not have sufficient intrinsic porosity to allow tissue ingrowth and are characterized by a very slow degradation rate. They also have poor setting characteristics and low compressive and flexural strength. Bioactive glasses (BGs) are synthetic silicabased bioactive materials that are biocompatible, resorbable and osteoinductive. They have the ability to bond to bone by forming a biologically active bone-like apatite layer on their surface that acts as a template for calcium phosphate precipitation and new bone formation. As a result, composite bioglass/calcium phosphate cements have been developed. Further in vitro studies have reported that fluoride-substituted hydroxyapatite augments osteoblastic activity and differentiation. In addition, studies have also shown that octacalcium phosphate (OCP) is more soluble when compared with calcium hydroxyapatite, and that the resorption of OCP is followed by new bone formation. Novel work previously performed by the authors, has successfully introduced BG into (i) hydroxyapatite, (ii) octacalcium phosphate and (iii) fluorohydroxyapatite cements without compromising the setting time. The aim of this study was to investigate bone formation and contact to these three novel BG/CPC cements following implantation in an ovine femoral condyle critical-sized defect. Our hypothesis was that the novel cements would augment bone formation to equal amounts when compared with a commercially available calcium phosphate cement (Hydroset™). Methods: Twenty-four 8 x 15 mm deep defects were created in the medial femoral condyles of 6 female, skeletally mature commercially cross-bred sheep. Ethical approval was granted and all procedures were carried out in compliance with the UK's Home Office Regulations (Animal Scientific Procedures Act 1986). The cements investigated were BG/CPC composites, however the calcium phosphate component was composed of either (1) OCP/Brushite (OCP), (2) a fluorohydroxyapatite (FHA) or (3) hydroxyapatite (HA). Groups 1 -3 were also compared with (4) Hydroset™, a commercially available calcium phosphate cement. Cements remained in vivo for 12 weeks (n=6). Fluorochrome markers (oxytetracycline and calcein green) were administered in order to measure bone apposition rates and following retrieval, specimens were processed for undecalcified histology. A thin histological section was made through the centre of each defect and image analysis techniques were used to quantify bone apposition rates and bone-implant contact at 12 weeks post surgery. The compressive strength (MPa) of each of the cements was tested using an indentation method (Zwick Proline 500) in
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